Physician profile
Steve T Kirk
NPI 1679708754
$57,078.61
in general payments reported to CMS, 2019-2025
71 companies · $5,348 in 2025
The $5,348 reported for 2025 was more than what 85% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,685 · 2020: $6,192 · 2021: $2,172 · 2022: $9,280 · 2023: $24K · 2024: $7,830 · 2025: $5,348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Consulting Fee: $7,965 · Food and Beverage: $7,844 · Honoraria: $4,100 · Travel and Lodging: $820 · Education: $252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,768.31 |
| Consulting Fee | $7,965.00 |
| Food and Beverage | $7,843.82 |
| Honoraria | $4,100.00 |
| Travel and Lodging | $819.93 |
| Education | $252.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $17,859.29 | 2019-2025 | |
| Avadel Cns Pharmaceuticals, LLC | $7,640.65 | 2023-2025 | Lumryz |
| Eisai INC. | $7,529.50 | 2020-2025 | |
| Idorsia Pharmaceuticals US INC | $7,330.43 | 2022-2023 | Quviviq |
| Axsome Therapeutics, INC. | $6,164.81 | 2023-2025 | Sunosi, Symbravo |
| Harmony Biosciences LLC | $1,588.87 | 2020-2025 | Wakix |
| Ucb, INC. | $1,101.73 | 2019-2025 | Briviact, Fintepla, Nayzilam |
| Supernus Pharmaceuticals, INC. | $1,064.67 | 2019-2021 | |
| Abbvie INC. | $824.87 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $609.04 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $447.99 | 2019-2024 | Ultomiris, Soliris |
| Sunovion Pharmaceuticals INC. | $353.83 | 2019-2022 | |
| Pfizer INC. | $349.01 | 2023-2025 | |
| Neurelis, INC. | $246.84 | 2022-2025 | Valtoco |
| Tg Therapeutics, INC. | $245.98 | 2023-2025 |
Show all 70 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steve Kirk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.